STUDY OF ERIBULIN MESYLATE IN COMBINATION WITH PEGYLATED RECOMBINANT HUMAN HYALURONIDASE (PEGPH20) VERSUS ERIBULIN MESYLATE ALONE IN SUBJECTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE, HIGH-HYALURONAN (HA) METASTATIC BREAST CANCER (MBC):